Depreotide 

Depreotide is a nove tumor tarcer, can be complexed with technetium-99m (^99mTc-depreotide) for optimal imaging properties. ^99mTc-depreotide somatostain receptor imaging has been playing an important role in medical diagnosis research^[1]. Depreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Depreotide, complexed with technetium-99m to form (99m)Tc-depreotide, binds somatostatin receptors (SSTRs) with high affinity to SSTRs 2, 3, and 5^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

99mTc-depreotide (sodium chloride 0.9% w/v solution; i.v.; single dose) shows a optimal image interpretation with SPECT images (Single Photon Emission Computed Tomography) between 2 and 4 hours following injection^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1357.69

C₆₅H₉₆N₁₆O₁₂S₂

161982-62-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Rodrigues M, et al. 99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. J Clin Endocrinol Metab. 2006 Oct;91(10):3997-4000.   [Content Brief]

  [2]. Halley A, et al. Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1026-32.  [Content Brief]